- The European Medicines Agency (EMA) has accepted for review Acorda Therapeutics' (NASDAQ:ACOR) marketing application seeking approval for INBRIJA (levodopa inhalation powder) for the treatment of OFF periods in Parkinson's disease patients taking a carbidopa/levodopa regimen.
- The agency's action date will be in late December based on a 210-day review period from the approximate validation date of May 29.
- The company's U.S. marketing application is currently under FDA review with an action date of October 5.